Search

Background: Patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) are at high risk of thrombosis. However, bleeding-related complications during antithrombotic therapy remain a major barrier to effective treatment and can often lead to adverse outcomes. This meta-analysis aimed to determine the efficacy and safety of bivalirudin and heparin in patients with ACS after PCI. Methods: Randomized controlled trials (RCTs) on the efficacy and safety of bivalirudin versus heparin in patients with ACS after PCI were identified from the PubMed, Embase, Cochrane Library, CBM, CNKI, WanFang, and VIP database until August 2024. The outcomes included all-cause mortality, major adverse cardiovascular events (MACEs), incidence of recurrent myocardial infarction, stent thrombosis, short-term bleeding, revascularization, and retransfusion. Meta-analysis was performed using RevMan 5.3 and Stata 12.0 softwares. The included studies were assessed for risk of bias using the Cochrane risk-of-bias assessment tool. Results: A total of 70,199 patients from 27 randomized controlled trials (RCTs) were analyzed in this review. There were no significant differences between the bivalirudin and heparin groups in terms of all-cause mortality, major adverse cardiovascular events (MACEs), recurrent myocardial infarction, stent thrombosis within 30 days, or subacute stent thrombosis. Specifically, the incidence of short-term bleeding (P = 0.001) and retransfusion (P = 0.001) was significantly lower in the bivalirudin group compared to the heparin group. Conversely, the incidence of acute stent thrombosis (P < 0.0001) and revascularization (P = 0.009) was significantly higher in the bivalirudin group. Conclusions: Compared with heparin, bivalirudin has definite anticoagulant effect in patients with acute myocardial infarction after PCI, and the risk of bleeding and the incidence of retransfusion were lower in the bivalirudin group. This review helps doctors in PCI management choose bivalirudin or heparin more precisely based on patients' conditions for better treatment and fewer adverse events. [ABSTRACT FROM AUTHOR]

The aim of this study was to investigate the value of introvoxel incoherent motion diffusion-weighted magnetic resonance imaging (IVIM-DWI) in the diagnosis of benign and malignant ovarian tumor. There were 108 patients with ovarian tumors who were selected to compare the differences of IVM-DWI parameters between benign and malignant tumors. The results showed that the IVIM-DWI parameters including apparent diffusion confident (ADC), slow diffusion confident (Disown) and fast diffusion confident score (f value) of malignant tumor were lower than that of benign tumor (P$0. 05). The area under ROC curve of ADC, Slow and f value in the diagnosis of malignant ovarian tumor were 0. 816, 0. 915 and 0. 852, respectively (P$0. 05). ADC and Disown were negatively correlated with carbohydrate antigen 125(CA125) (r= -- 0. 457 and --0. 553, P$0. 05). The ADC in patients whit Hal stage was significantly lower than that of patients I -- (P$0. 05). In a word, IVIM-DWI parameters have a certain value in the diagnosis of benign and malignant ovarian tumors, and the ADC, Do levels are corrected with CA125 and Hal stage of patients with malignant tumors. [ABSTRACT FROM AUTHOR]